
VC firms back CHF 15.5m series-B extension for Oculis
Boston-based healthcare investor Tekla Capital Management has led a consortium of new and existing investors to provide Lausanne-based biopharmaceutical company Oculis with a CHF 15.5m series-B funding round extension.
Nan Fung Life Sciences was also a new investor in the round and was joined by unnamed previous backers. Brunnur Ventures, Silfurberg, Bay City Capital, Novartis Venture Fund and Pivotal BioVenture Partners have all previously invested in the business, according to Unquote Data.
The fresh capital will be used to expand the company’s portfolio through strategic in-licensing, and to advance the development of its pipeline of eyedrop treatments for ophthalmic diseases.
The company simultaneously announced its first in-licensing agreement for a topical anti-TNF alpha antibody from Novartis. Proceeds from the funding round were used to finance the agreement but no further financial details were disclosed.
Tekla’s Henry Skinner will join Oculis’ board as non-executive director. Stefan Sveinsson, the former head of R&D at Actavis, will step down from the board; he joined in 2016 following the initial closing of the company’s series-B.
Previous funding
Icelandic investment firms Brunnur and Silfurberg led a series-A funding round for Oculis in 2016.
Bay City Capital led a CHF 20m series-B funding round for the firm in 2017 alongside Novartis Venture Fund, Pivotal BioVenture Partners, Brunnur Ventures and Silfurberg.
Company
Oculis is a clinical-stage biotechnology company focused on the development of topical treatments for ophthalmic diseases, for both back and front of the eye. Headquartered in Lausanne, Switzerland, with research operations in Reykjavik, Iceland, Oculis was founded by Einar Stefánsson and Thorsteinn Loftsson in 2014.
People
Oculis – Riad Sherif (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater